Method of treating ocular conditions by administering an antibody that activates Tie2 and binds VEGF
The disclosure provides compositions comprising multi-specific compounds, including a compound that targets a phosphatase and a receptor tyrosine kinase agonist. Also provided are methods for the treatment of conditions associated with angiogenesis, comprising administering a multi-specific compound that targets a phosphatase and a receptor tyrosine kinase agonist.
1. A method of treating an ocular condition in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an antibody comprising:
(a) a first domain that activates Tie2; and
(b) a second domain that specifically binds a VEGF and inhibits VEGF function.
2. The method of claim 1 , wherein the ocular condition is diabetic retinopathy.
3. The method of claim 1 , wherein the ocular condition is neovascularization.
4. The method of claim 1 , wherein the ocular condition is vascular leak.
5. The method of claim 1 , wherein the ocular condition is increased intraocular pressure.
6. The method of claim 1 , wherein the ocular condition is ocular edema.
7. The method of claim 1 , wherein the ocular condition is diabetic macular edema.
8. The method of claim 1 , wherein the ocular condition is wet age-related macular degeneration.
9. The method of claim 1 , wherein the ocular condition is ocular inflammation.
10. The method of claim 1 , wherein the ocular condition is retinal vein occlusion.
11. The method of claim 1 , wherein the administration is to an eye of the subject.
12. The method of claim 1 , wherein the administration is intravitreal.
13. The method of claim 1 , wherein the administration is subcutaneous.
14. The method of claim 1 , wherein the administration is systemic.
15. The method of claim 1 , wherein the subject is a human.
16. The method of claim 1 , wherein the therapeutically effective amount is from about 0.25 mg to about 200 mg.
17. The method of claim 1 , wherein the therapeutically effective amount is from about 1 mg/kg to about 10 mg/kg.
18. The method of claim 1 , wherein the therapeutically effective amount is from about 1 mg to about 50 mg.
19. The method of claim 1 , wherein the therapeutically effective amount is from about 50 mg to about 200 mg.